Oxford Centre for Haematology
The OCH Management Board has as members the Director of the OCH, the Head of Clinical Haematology, the Head of Laboratory Haematology, the Head of the Radcliffe Department of Medicine, the Head of the Nuffield Division of Clinical Laboratory Sciences, the Director of the MRC Molecular Haematology Unit, the Director of the MRC Human Immunology Unit, the RDM Research Strategy Coordinator and the Administrator of the OCH.
Reactivation of a developmentally silenced embryonic globin gene.
King AJ. et al, (2021), Nat Commun, 12
Expected individual benefit of prophylactic platelet transfusions in hemato-oncology patients based on bleeding risks.
Cornelissen LL. et al, (2021), Transfusion
Emergency departments are higher-risk locations for wrong blood in tube errors.
Dunbar NM. et al, (2021), Transfusion
International Forum on Policies and Practice for Transfusion of
Non‐Identical Platelets: Summary
Cardigan R. et al, (2021), Vox Sanguinis
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Arabi YM. et al, (2021), Intensive Care Med
30 March 2021
Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.
28 June 2021: Oxford Centre for Haematology Annual Meeting
Please email for further information